New Stock News | L.B. Pharmaceutical's Hong Kong Stock IPO and domestic unlisted shares "fully tradable" approved by the China Securities Regulatory Commission.

On April 30th, the International Cooperation Department of the China Securities Regulatory Commission issued the "Filing Notice on Overseas Issuance and Listing of Labon Pharmaceutical (Jiangsu) Co., Ltd. and the Conversion of Domestic Unlisted Shares to 'Full Circulation'". The company plans to issue no more than 65,268,700 shares of overseas listed common stock and list them on the Hong Kong Stock Exchange. A total of 45 shareholders of the company intend to convert a total of 170,366,789 shares of domestically unlisted shares into overseas listed shares and list them on the Hong Kong Stock Exchange for circulation. According to the prospectus, Labon Pharmaceutical is a globally leading biopharmaceutical company focusing on the field of kidney diseases. Based on Zhi Shi consultation's information, the company has the most comprehensive innovative product portfolio for kidney diseases, with the widest range of indications. The CKD market is huge, valued at billions of dollars, with tremendous growth potential. Labon Pharmaceutical has built a vertically integrated platform covering research and development, production, and commercialization. The names and quantities of shareholders for the "Full Circulation" are as follows: